Traws Pharma CFO awarded 90,000 stock options

Traws Pharma, Inc. reported that Chief Financial Officer Parker Charles Nolan received a grant of 90,000 stock options to purchase common stock.

Rhea-AI Filing Summary

Traws Pharma, Inc. reported that Chief Financial Officer Parker Charles Nolan received a grant of 90,000 stock options to purchase common stock. The options have an exercise price of $0.68 per share, vest 100% on the first anniversary of the July 9, 2026 grant date, and expire on July 9, 2036. The award was approved by the compensation committee of independent directors under the company’s 2021 Incentive Compensation Plan. Following this grant, Nolan holds 90,000 stock options directly.

Insider Trade Summary

Grant/Award: 90,000 shares

Grant/Award 1 txn

Insider Parker Charles Nolan

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	90,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 90,000 contracts (Direct)

Footnotes (1)

1. F1. Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

Key Figures

Stock options granted: 90000.0000 options Exercise price: $0.6800 per share Underlying shares: 90000.0000 shares +3 more

6 metrics

Stock options granted 90000.0000 options Grant to CFO Parker Charles Nolan on 2026-07-09

Exercise price $0.6800 per share Exercise price for the 90,000 stock options

Underlying shares 90000.0000 shares Common stock underlying the stock option award

Vesting date 2027-07-09 Options vest 100% on the first anniversary of grant

Expiration date 2036-07-09 Expiration date of the stock option award

Options held after transaction 90000.0000 options Total stock options held directly by CFO after grant

Key Terms

Stock Option (right to buy), exercise price, Incentive Compensation Plan, vest 100%

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 0.6800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Incentive Compensation Plan financial

"under the Issuer's 2021 Incentive Compensation Plan"

An incentive compensation plan is a formal program that rewards employees and executives with bonuses, stock, or other payments tied to specific performance goals—such as revenue, profit, productivity, or long‑term share price. Investors watch these plans because they shape how leaders make decisions and take risks; like paying a coach by wins rather than effort, well‑designed plans can drive sustainable growth while poor designs can encourage short‑term behaviors that harm shareholder value.

vest 100% financial

"The stock options under this award will vest 100% on the first anniversary"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Traws Pharma (TRAW) report for CFO Parker Charles Nolan?

Traws Pharma reported that CFO Parker Charles Nolan received a grant of 90,000 stock options to buy common stock. The options were awarded as part of his compensation under the 2021 Incentive Compensation Plan and are held directly.

How many stock options were granted to the TRAW CFO and at what exercise price?

The CFO received 90,000 stock options with an exercise price of $0.68 per share. These options give him the right to purchase Traws Pharma common stock at that fixed price once vested.

When do the TRAW CFO’s newly granted stock options vest?

The stock options granted to the CFO vest 100% on the first anniversary of the July 9, 2026 grant date. This means the entire 90,000-option award becomes exercisable on July 9, 2027.

What is the expiration date of the TRAW CFO’s 90,000 stock options?

The CFO’s 90,000 stock options expire on July 9, 2036. After that date, any unexercised options become worthless and can no longer be used to purchase Traws Pharma common stock.

Under which plan were the TRAW CFO’s stock options granted?

The options were awarded under Traws Pharma’s 2021 Incentive Compensation Plan, as amended and/or restated. The grant was approved by the company’s compensation committee of independent directors overseeing executive compensation.

How many stock options does the TRAW CFO hold after this grant?

Following this grant, the CFO holds 90,000 stock options directly. This total reflects the newly awarded options reported, giving him future rights to acquire Traws Pharma common stock upon vesting and exercise.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/14/2026 - 08:22 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parker Charles Nolan

(Last) (First) (Middle)

C/O TRAWS PHARMA, INC

12 PENNS TRAIL

(Street)

NEWTOWN PENNSYLVANIA 18940

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Traws Pharma, Inc. [ TRAW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.68	07/09/2026		A		90,000		07/09/2027(1)	07/09/2036	Common Stock	90,000	$0	90,000	D

Explanation of Responses:

1. Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

	/s/ Charles N. Parker	07/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)